[Association between gut microbiota and hyperuricemia: insights into innovative therapeutic strategies].

Q4 Biochemistry, Genetics and Molecular Biology
Shujuan Zhang, Xiaoqiu Liu, Yuxin Zhong, Yu Fu
{"title":"[Association between gut microbiota and hyperuricemia: insights into innovative therapeutic strategies].","authors":"Shujuan Zhang, Xiaoqiu Liu, Yuxin Zhong, Yu Fu","doi":"10.13345/j.cjb.250060","DOIUrl":null,"url":null,"abstract":"<p><p>Uric acid (UA) is the final metabolite of purines in the human body. An imbalance in UA production and excretion that disrupts homeostasis leads to elevated blood UA levels and the development of hyperuricemia (HUA). Approximately one-third of UA is excreted through the intestinal tract. As a crucial component of the intestinal microenvironment, the gut microbiota plays a pivotal role in regulating blood UA levels. Alterations or imbalances in gut microbiota composition are linked to the onset of HUA, which implies the potential of gut microbiota as a novel target for the prevention and treatment of HUA. This review introduces the occurrence mechanism and damage of hyperuricemia, examines the association between HUA and the gut microbiota and their metabolites, and explores the molecular mechanisms underlying gut microbiota-targeted therapies for HUA. Furthermore, it discusses the potential applications of probiotics, prebiotics, and traditional Chinese medicine (including both single herbs and compound formulas) with UA-lowering effects, along with cutting-edge technologies such as fecal microbiota transplantation and machine learning in HUA treatment. This review provides valuable perspectives and strategies for improving the prevention and treatment of HUA.</p>","PeriodicalId":21778,"journal":{"name":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","volume":"41 6","pages":"2290-2309"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13345/j.cjb.250060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Uric acid (UA) is the final metabolite of purines in the human body. An imbalance in UA production and excretion that disrupts homeostasis leads to elevated blood UA levels and the development of hyperuricemia (HUA). Approximately one-third of UA is excreted through the intestinal tract. As a crucial component of the intestinal microenvironment, the gut microbiota plays a pivotal role in regulating blood UA levels. Alterations or imbalances in gut microbiota composition are linked to the onset of HUA, which implies the potential of gut microbiota as a novel target for the prevention and treatment of HUA. This review introduces the occurrence mechanism and damage of hyperuricemia, examines the association between HUA and the gut microbiota and their metabolites, and explores the molecular mechanisms underlying gut microbiota-targeted therapies for HUA. Furthermore, it discusses the potential applications of probiotics, prebiotics, and traditional Chinese medicine (including both single herbs and compound formulas) with UA-lowering effects, along with cutting-edge technologies such as fecal microbiota transplantation and machine learning in HUA treatment. This review provides valuable perspectives and strategies for improving the prevention and treatment of HUA.

[肠道微生物群与高尿酸血症之间的关系:对创新治疗策略的见解]。
尿酸(UA)是嘌呤在人体内的最终代谢产物。尿酸产生和排泄失衡,破坏体内平衡,导致血尿酸水平升高和高尿酸血症(HUA)的发展。大约三分之一的UA通过肠道排出。肠道菌群作为肠道微环境的重要组成部分,在调节血液UA水平中起着关键作用。肠道微生物群组成的改变或不平衡与HUA的发病有关,这意味着肠道微生物群有可能成为预防和治疗HUA的新靶点。本文介绍了高尿酸血症的发生机制和损害,探讨了HUA与肠道微生物群及其代谢物的关系,并探讨了肠道微生物群靶向治疗HUA的分子机制。此外,它还讨论了具有降低ua效果的益生菌,益生元和中药(包括单一草药和复方)的潜在应用,以及粪便微生物群移植和机器学习等尖端技术在HUA治疗中的应用。本文综述为改善HUA的预防和治疗提供了有价值的观点和策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Sheng wu gong cheng xue bao = Chinese journal of biotechnology
Sheng wu gong cheng xue bao = Chinese journal of biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
1.50
自引率
0.00%
发文量
298
期刊介绍: Chinese Journal of Biotechnology (Chinese edition) , sponsored by the Institute of Microbiology, Chinese Academy of Sciences and the Chinese Society for Microbiology, is a peer-reviewed international journal. The journal is cited by many scientific databases , such as Chemical Abstract (CA), Biology Abstract (BA), MEDLINE, Russian Digest , Chinese Scientific Citation Index (CSCI), Chinese Journal Citation Report (CJCR), and Chinese Academic Journal (CD version). The Journal publishes new discoveries, techniques and developments in genetic engineering, cell engineering, enzyme engineering, biochemical engineering, tissue engineering, bioinformatics, biochips and other fields of biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信